Medication Cost Savings — the article + the world, ranked

A fuller editorial guide to medication cost savings is coming soon. For now, the ranking below compares every country we have assessed on it — open a country's report for the cited detail behind its score.

The country comparison

Which countries are best for medication cost savings

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

1 Thailand TH 4.5/5 Good Thailand offers extraordinary medication cost savings at 92.9% below global median—substantially exceeding the Score 5 threshold of 60%—with documented annual savings exceeding $1000+ and specialized medical tourism i... Full report
The evidence behind this score 5 cited points
- Overall medication costs 92.9% below global median (lowest in 50-country Medbelle survey), with 97-98% savings on Lipitor, 87% on insulin vs US prices
- Bumrungrad International Hospital Medication Tourism program offers up to 80% savings on specialty pharmaceuticals with specialized pharmacy services and multilingual support
- Generic drug market: 94 billion Thai baht in 2021 with 6-22% price reductions through competition; CAR T-cell therapy $250k-$500k vs $1M in US (50-75% savings)
- Thai FDA regulatory oversight with GMP certification requirements and bioequivalence assurance; government price controls and reference pricing for essential medicines
- Export regulations allow 90-day supplies of Schedule II/III narcotics with permit; non-controlled medications limited to 30-day supplies; government programs (UCS) primarily benefit Thai citizens rather than medical tourists
Read the full Thailand report →
2 Spain ES 4.5/5 Good Spain delivers excellent medication cost savings of 60–90% below major source countries—exceeding even the Score 5 price threshold—with insulin costs approximately 9 times lower than the US and government-mandated pri... Full report
The evidence behind this score 5 cited points
- Brand-name drug prices are 60–90% lower in Spain than the US, with insulin at $2.51/defined daily dose vs. $22.68 in the US (ninefold difference)
- Generic drugs comprise 65% of all prescriptions, with mandatory substitution of the cheapest bioequivalent under Spain's EFG system
- Government pricing programs: EU citizens with EHIC pay 50% co-payment on the government-set retail price; a 2026 reform introduced €8.23/month maximum co-payment cap for non-resident foreigners
- Telemedicine prescription services (€15–30) and English-speaking pharmacy staff in tourist areas provide practical access pathways for non-EU tourists
- Spain lacks dedicated medical tourism pharmacy infrastructure compared to dedicated medical tourism destinations; prescriptions are accessed through standard community pharmacies (22,000+)
Read the full Spain report →
3 India IN 4.5/5 Good India demonstrates exceptional medication cost savings of 60-90% across most drug categories, with insulin at $8.81 vs $98.70 in the US and cancer drugs receiving price cuts up to 85%. The 70% generic market penetrati... Full report
The evidence behind this score 8 cited points
- Insulin pricing: $8.81 in India vs $98.70 in US, representing 91% cost savings
- Cancer drug cost reductions: 42 non-scheduled anti-cancer drugs received price cuts up to 85% under NPPA order
- Generic drug market penetration: 70% of pharmaceutical market as of 2023
- Government price regulation: NPPA controls prices of 871 essential drugs through DPCO-2013
- Annual savings potential: Medical tourists managing chronic disease can save over $1,000 annually
- Quality concerns: 3% of drugs sold in retail outlets found to be substandard or spurious (2014-2016 national survey)
- Government subsidy programs: Jan Aushadhi Kendras offer 50-90% savings but primarily serve domestic patients, not medical tourists
- Medical tourism scale: $9 billion sector with 2 million annual patients from 78 countries
Read the full India report →
4 Turkey TR 4.5/5 Good Turkey offers exceptional medication cost savings—brand-name drugs are 172-1,028% cheaper than U.S. prices, insulin costs approximately $0.65 vs. $22.68 in the U.S., and cancer therapies are 50-70% cheaper. The countr... Full report
The evidence behind this score 7 cited points
- RAND study documents U.S. drug prices at 172%-1,028% of Turkish prices across all drug categories; insulin approximately 35x cheaper in Turkey ($0.65 vs. $22.68 USD)
- Chemotherapy costs $1,000-$3,500 per cycle in Turkey versus $10,000-$30,000 in U.S. (50-70% savings); targeted therapy approximately $2,500/month vs. $27,000+/month in U.S.
- No pharmaceutical subsidy programs (SGK) accessible to foreign visitors; medical tourists pay full unsubsidized retail prices
- Generic drugs capture approximately 65% of pharmaceutical volume; robust domestic manufacturing base with 70+ production facilities
- Approximately 28,000 independent licensed pharmacies with duty pharmacy (24/7) coverage; major hospitals operate dedicated international patient centers with multilingual pharmacy services
- TİTCK pharmaceutical regulatory authority with GS1 DataMatrix track-and-trace system processing 45 million daily transactions; $1 billion annual savings from preventing counterfeiting
- Documented availability issues for certain innovative oncology medications due to pharmaceutical company market withdrawals from Turkey
Read the full Turkey report →
5 Malaysia MY 4.0/5 Good Malaysia delivers substantial medication cost savings (70-90% for US-origin patients; 79-90% below global median) with adequate pharmacy infrastructure for medical tourists and solid regulatory oversight. Documented a... Full report
The evidence behind this score 5 cited points
- Malaysia ranks 3rd cheapest globally with combined drug prices 90.8% below global median; US prices +306.82% above median, enabling 70-90% savings for US-origin patients
- No pharmaceutical subsidy programs accessible to medical tourists; foreigners access private sector at market rates without preferential programs
- Private-sector generic market penetration at 49.1% (below Score 4 target of 60-79%); generic prices average 79.04% below global median
- JCI-accredited hospitals with comprehensive inpatient/outpatient/oncology pharmacies and international patient services; MHTC airport concierge support
- Documented annual medication savings of $500-5000+ across insulin ($1800+ annually), cancer biologics (83% reduction for trastuzumab), and chronic disease management
Read the full Malaysia report →
6 Germany DE 4.0/5 Good Germany delivers substantial medication cost savings of 40-60%+ across major drug categories (insulin 89% cheaper, biologics 60-82% cheaper) with transparent uniform pricing and excellent regulatory oversight. The gen... Full report
The evidence behind this score 5 cited points
- Insulin costs $11/vial in Germany vs. $99 in US (89% savings); adalimumab $1,570/month vs. $4,000-$9,000 in US (60-82% cheaper); mean cancer drug launch prices 37% lower than US
- Medical tourists excluded from statutory GKV insurance but receive same uniform regulated pharmacy prices as all self-paying patients; transparent pricing via Lauer Taxe, BfArM, and Pharmazie.com databases
- Generic drug market penetration 75-77% by volume, largest in Europe; comprehensive reference pricing system and AMNOG benefit assessment controlling costs
- Personal-use non-controlled medications export without restriction; clear BfArM procedures for controlled substances; multilingual pharmacy services available (Internationale Ludwigs-Apotheke processes international prescriptions via email)
- All medications hold EMA/BfArM authorization, comply with EU GMP standards, tracked under Falsified Medicines Directive since 2019; documented savings of $1,000-$5,000 annually for chronic disease patients
Read the full Germany report →
7 Israel IL 4.0/5 Good Israel delivers substantial medication cost savings of 60-80% below US retail prices through robust pharmaceutical infrastructure including IsraelPharm online pharmacy and hospital-based services, coupled with strong ... Full report
The evidence behind this score 6 cited points
- Israeli brand-name prescription prices are 60-80% below US retail equivalents; RAND analysis shows US prices average 2.78× those in 33 peer nations including Israel
- IsraelPharm serves 50,000+ international customers with 100,000+ orders shipped globally; free delivery on orders over $99
- Teva Pharmaceutical holds 35% of Israel's domestic generic market; government mandates generic substitution and INN prescribing; generic drugs typically 50-80% cheaper than brand equivalents
- Medical tourists explicitly excluded from subsidized copayment programs (10% for generics, 15% for branded drugs for citizens); tourists pay full regulated retail prices
- 30-day pharmacy prescription limit for locals, though 90-day personal import of non-controlled medications allowed for travelers
- Transparent pricing via publicly searchable Ministry of Health Israeli Drug Registry; strong regulatory framework with Ministry of Health oversight, no documented counterfeit issues, and JCI accreditation at major hospitals
Read the full Israel report →
8 Mexico MX 4.0/5 Good Mexico achieves strong 40-59% price reductions on average (meeting Score 4), with excellent pharmacy infrastructure, transparent pricing, clear export procedures, and documented annual savings exceeding $1000 for chro... Full report
The evidence behind this score 5 cited points
- U.S. drug prices are 1.72 times those in Mexico (42% below average), with certain medications reaching up to 80% savings
- Generic drugs represent 65% of market by value and 80% by volume, providing strong lower-cost alternatives
- Farmacias Guadalajara operates 2,944 branches across all 32 states; Farmacias del Ahorro operates 1,800+ branches with attached physician consultations costing $3.50-$22 USD
- Documented annual savings of $1000+ for common chronic disease medications; insulin savings often several thousand dollars (3-month supply: $600 in Mexico vs $3,700 in US)
- COFEPRIS regulatory oversight ensures compliance with Good Manufacturing Practices and international quality standards; 20 of 25 largest pharmaceutical companies present
Read the full Mexico report →
9 Colombia CO 4.0/5 Good Colombia offers strong prescription medication cost advantages with 70-90% savings on generics compared to U.S. prices, supported by comprehensive price regulation and excellent pharmacy infrastructure including 1,000... Full report
The evidence behind this score 5 cited points
- Generic medications cost 70-90% less than U.S. list prices, with documented examples: Restasis $50/month in Colombia vs. $500/month in U.S. (saving $2,700 annually); ciprofloxacin $1.75, amoxicillin $2.00, omeprazole $1.00
- Tourist-visa holders have zero access to government subsidy programs (PBS/SGSSS enrollment); all medical tourists pay commercial retail prices rather than subsidized institutional prices
- Generic drugs represent 42% of total pharmaceutical sales by value, providing moderate generic market penetration
- Excellent pharmacy infrastructure: Cruz Verde operates 1,000+ locations with 24/7 hours, in-store medical consultations ($20-50 USD), same-day Rappi delivery in Bogotá/Medellín, and hospital pharmacies at JCI-accredited institutions
- Clear export regulations: 30-90 day personal supply allowed with prescription copy or doctor's letter; controlled substances require physician letter with 30-day limit
Read the full Colombia report →
10 Japan JP 3.5/5 Moderate Japan offers extraordinary medication cost savings (60-86% below US prices) with world-class generic penetration (89.3%) and completely transparent NHI pricing. However, the absence of government subsidy programs for ... Full report
The evidence behind this score 5 cited points
- US insulin prices 8.4× higher than Japan ($22.68/100 IU vs $3.20), enabling 86% savings for medical tourists paying full NHI-listed price
- Generic drug market penetration of 89.3% as of December 2024, among the world's highest
- NHI price list is publicly available and uniformly enforced, providing complete price transparency to tourists
- Zero government subsidy programs accessible to medical tourists—NHI covers only residents with 3+ month stays
- Export of purchased medications requires government application with minimum 2-week processing time, creating legal complexity
Read the full Japan report →
11 Hungary HU 3.5/5 Moderate Hungary offers substantial medication cost savings (40-93% below US prices) with a strong generic drug market and excellent subsidized pharmaceutical access for EU/EEA tourists holding EHIC cards. However, the country... Full report
The evidence behind this score 5 cited points
- Insulin pricing at $1.58/vial versus $22.68 in US (93% lower); US brand-name drugs average 278% of OECD prices, placing Hungary at approximately 36% of US retail prices
- NEAK state subsidies of 25-80% accessible to EHIC-holding EU/EEA tourists covering 92% of prescriptions; named-patient reimbursement available for unlisted medications as of January 2025
- Generic market strength documented by 59% statin spending reduction following generic competition; Hungary maintains one of the highest generic prescribing rates in the EU
- Severe drug shortages affecting 14,000 pharmaceutical types simultaneously; Europe's highest cancer death rate at 275 per 100,000 versus 175 EU average; bladder cancer recurrence rates tripled from 16% to 43% due to BCG shortage
- NNGYK is WHO Listed Authority with strong regulatory oversight; no dedicated medical tourism pharmacy infrastructure exists comparable to other medical tourism destinations
Read the full Hungary report →
12 Poland PL 3.5/5 Moderate Poland offers substantial medication cost savings (80-90% vs. US prices) with insulin at $1.43 vs. $22.68 and semaglutide at ~$100 vs. $936, substantially exceeding the Score 4 threshold of $500-999 annual savings. A ... Full report
The evidence behind this score 5 cited points
- Insulin costs $1.43 in Poland vs. $22.68 in the US (94% savings); semaglutide costs ~$100 per pen vs. $936/month in the US (89% savings)
- Poland's pharmaceutical prices are 82% of the EU average; generic market accounts for ~70% of sales by volume with generic prices ~35% below EU average
- No government subsidy programs accessible to uninsured medical tourists; NFZ reimbursement requires PESEL national ID number, unavailable to foreigners
- No dedicated medical tourism pharmacy infrastructure; Polish pharmacists documented as feeling ill-prepared to serve non-Polish speakers, with adequate multilingual services limited to major cities (Warsaw, Kraków, Wrocław, Gdańsk)
- Personal use export limit of 5 packages per medication prevents bulk purchasing; strong EU regulatory oversight with serialization system and GMP compliance provides quality assurance
Read the full Poland report →
13 South Korea KR 3.5/5 Moderate South Korea offers exceptional underlying medication prices (74% below US, far exceeding the 60% threshold for Score 5), with outstanding insulin savings (~90%) and lowest anticancer drug prices globally. However, med... Full report
The evidence behind this score 6 cited points
- Prescription drug prices 74.4% below US ($25.6% of US cost); brand-name drugs 7x cheaper; biologics 5.7x cheaper
- National Health Insurance requires 6+ month residency—short-term medical tourists cannot access subsidized pricing despite excellent nominal costs
- Generic drug prices 2.17x OECD average with low market penetration; generic drugs in Korea 92.3% lower usage than G20 countries
- No specialized medical tourism pharmacy infrastructure; pharmacies abundant in major cities but standard healthcare system only
- Three-month export limit for personal use and no mail-order option due to controlled substance prohibitions; pre-travel MFDS approval required for many medications
- Documented savings: insulin $10.30 vs $99/unit (90% saving); monoclonal antibody therapy potential $30k savings on $150k US cost; regulatory framework ensures quality and transparency
Read the full South Korea report →
14 Brazil BR 3.5/5 Moderate Brazil delivers strong documented savings of 40-90%+ on common prescription medications (Eliquis 92% savings, semaglutide 45-80%), exceeding the moderate threshold and approaching good-level savings for conventional m... Full report
The evidence behind this score 5 cited points
- Documented savings of 40-90%+ for common medications: Eliquis (~92% savings), colchicine (~99% savings), semaglutide/Ozempic (45-80% savings vs. U.S. prices)
- Generic market represents only 35-38% of total pharmaceutical market value, though penetration reaches 70%+ in specific therapeutic categories (hypertension 73%, cholesterol 78%, anxiety 71%)
- Biologic medicines are severely overpriced in Brazil's private sector: bevacizumab 541% more expensive than New Zealand, infliximab 1,054% more expensive than France, pembrolizumab 225% more expensive than Canada
- Government subsidy programs (Farmácia Popular, SUS) are inaccessible to medical tourists; require CPF and legal residency registration
- Robust pharmacy infrastructure with ~100,000 private pharmacies nationwide, 24-hour operations, e-prescription system, and telemedicine platforms specifically serving international patients (consultation fees $30-$80 USD)
Read the full Brazil report →
15 United Kingdom GB 3.0/5 Moderate While UK medication costs are 60%+ below US prices for high-cost drugs and generics comprise 80% of NHS prescriptions by volume, medical tourists face critical accessibility barriers including complete exclusion from ... Full report
The evidence behind this score 5 cited points
- US prescription drug prices are 2.78 times those in UK comparator countries, with insulin 10x more expensive ($98.70 vs $7.52 per unit) and Ozempic approximately 10x higher ($936/month vs £150-300) — RAND Corporation and Peterson-KFF 2024
- NHS pharmaceutical subsidies are completely inaccessible to overseas visitors; medical tourists must pay full private market rates plus £89-125 physician consultation fees — Citizens Advice and London Doctors Clinic 2024
- No government pharmaceutical subsidy programs, no bilateral healthcare agreements, and no dedicated medical tourism pharmacy infrastructure exist — explicitly documented across multiple NHS and clinic sources
- Generic and biosimilar medicines comprise 80% of NHS-prescribed medicines by volume, but private market pricing is non-transparent and varies substantially by pharmacy — Medicines UK 2024 and Oxford Online Pharmacy 2024
- Almost 57% of generic medicines were in short supply for more than 6 months in 2024, affecting ADHD medications, GLP-1 weight loss drugs, and menopause treatments commonly sought by medical tourists — Medscape 2024
Read the full United Kingdom report →
16 Jordan JO 2.5/5 Moderate Jordan offers modest medication cost savings for American tourists on brand-name drugs (likely 30-40% below US retail), but provides no cost advantages—and potentially higher prices—for European tourists. The country ... Full report
The evidence behind this score 6 cited points
- Private-sector originator brands priced at 9.7× international reference prices; all investigated drugs more expensive than UK prices [BMC Health Services Research 2018, ISPOR comparison]
- No government subsidy or pharmaceutical benefit programs accessible to medical tourists or temporary residents; foreign patients pay full regulated retail prices [JFDA / Jordan Times 2025]
- Generic market penetration of 76% at availability level, but generics only drop ~15% at launch versus originator brands, compared to ~90% price drop in the UK [ISPOR 13th Annual European Congress]
- No documented network of specialized medical tourism pharmacies with multilingual services, streamlined prescription filling, or international insurance claim processing; services provided through standard domestic channels [health-care and pharmacy practice literature]
- Strong regulatory quality: Jordan is only second Arab nation to achieve PIC/S membership; 13 major pharmaceutical manufacturers hold WHO-GMP and EU-GMP certifications; JFDA conducts active price reduction rounds [Jordan News 2021, Jordan Times 2025]
- Jordan attracts 225,000 international medical patients annually, predominantly from Iraq, Saudi Arabia, Yemen, and Libya—countries that seek procedure cost savings (70-80% below US), not medication cost advantages [U.S. International Trade Administration 2024]
Read the full Jordan report →
17 Singapore SG 2.0/5 Poor Singapore offers minimal medication cost savings for medical tourists. While uninsured US patients may see 40-75% savings vs US list prices on specific drugs, this advantage erodes significantly when US assistance pro... Full report
The evidence behind this score 6 cited points
- Foreign nationals are 'categorically ineligible for all MOH subsidy programmes'—MediShield Life, Medifund, and MAF all restricted to citizens/permanent residents only
- For European patients 'who already pay WHO-comparable prices, Singapore is generally no cheaper for medications, and often costs more'
- MOH acknowledges Singapore medicine prices are 'generally higher than in some neighbouring countries'
- When US insulin assistance programs are factored in (Sanofi USD 35/month cap), 'the calculus weakens considerably for many drugs'
- No documented 'medical tourism pharmacies' or 'pharmaceutical cost bundling in Singapore medical tourism packages'
- Report's conclusion: 'Singapore's medical tourism strength lies in procedural excellence...not in pharmaceutical cost savings. Patients travelling primarily to secure cheaper medications will find better value in Malaysia, Thailand, or India'
Read the full Singapore report →
18 United Arab Emirates AE 1.5/5 Poor The UAE is structurally an expensive pharmaceutical market, not a cost-savings destination for medical tourists. Research shows 84.4% of UAE medicines cost more than double Australian prices (median 4.40× higher), ran... Full report
The evidence behind this score 5 cited points
- 84.4% of UAE medicines cost more than double Australian prices (median price ratio 4.40); UAE ranked 3rd most expensive globally, 122% above global average
- No pharmaceutical subsidy programs extend to medical tourists or foreign visitors; mandatory health insurance covers residents and employees only
- Mandatory local UAE prescription requirement: foreign prescriptions not recognized; specialist consultations cost AED 400–1,200 ($109–$327) per visit
- Limited savings only for US-based patients on select drugs (e.g., Humira ~$1,970 UAE vs. $7,300 US); for European and Australian patients, UAE prices typically exceed home costs
- Excellent regulatory oversight (Tatmeen system, 7,300+ products, 280M+ transactions) and extensive pharmacy infrastructure (2,000+ outlets) do not offset structural price disadvantage
Read the full United Arab Emirates report →
19 United States US 1.0/5 Poor The United States offers no medication cost savings for medical tourists and is fundamentally incompatible with pharmaceutical tourism focused on affordability. U.S. prices are 2.78-4.22 times higher than comparison c... Full report
The evidence behind this score 5 cited points
- U.S. prices across all drugs are 2.78 times higher than comparison countries, with brand-name drugs averaging 4.22 times those in comparison nations
- Insulin prices are nearly 10 times higher in the U.S. ($98.70/vial) than in OECD comparison countries ($8.81/vial average)
- No government subsidy programs accessible to foreign patients and no specialized medical tourism pharmacy infrastructure
- Biologics for serious conditions cost $10,000-$100,000+ annually with no assistance programs for international patients
- Reverse medical tourism pattern: millions of U.S. residents travel annually to Mexico and Canada for cheaper medications
Read the full United States report →

See the full ranking, the 1–5 rubric and the reports →